A Multicenter, Open-Label Trial to Evaluate the Quality of Life in Adults with ADHD Treated with Long-Acting Methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) Study

Autor/inn/en	Mattos, Paulo; Rodrigues Louza, Mario; Fernandes Palmini, Andre Luis; de Oliveira, Irismar Reis; Lopes Rocha, Fabio
Titel	A Multicenter, Open-Label Trial to Evaluate the Quality of Life in Adults with ADHD Treated with Long-Acting Methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) Study
Quelle	In: Journal of Attention Disorders, 17 (2013) 5, S.444-448 (5 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	1087-0547
DOI	10.1177/1087054711434772
Schlagwörter	Quality of Life; Drug Therapy; Attention Deficit Hyperactivity Disorder; Outcomes of Treatment; Symptoms (Individual Disorders); Stimulants; Foreign Countries; Scores; Brazil; Hamilton Rating Scale for Depression; State Trait Anxiety Inventory + Suchen Sie Ihr Suchwort? Lebensqualität; Psychiatrische Symptomatik; Droge; Ausland; Brasilien
Abstract	The available literature provides few studies on the effectiveness of methylphenidate in improving quality of life in individuals with ADHD. Objective: To assess the effectiveness of Methyphenidate OROS formulation (OROS MPH) through QoL in adults with ADHD. Method: A 12-week, multicenter, open-label trial involving 60 patients was used. The measures used were Adult Self-Rating Scale, Adult ADHD Quality of Life Scale (AAQoL), State and Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression (CGI), and safety measures. A significance statistic level of 5% was adopted. Results: Analyses included 60 patients (66.7% male; M age = 31.1 years) for safety and 58 patients for effectiveness. All AAQoL subscales improved from baseline to Week 12 (p less than .0001), as well as the Total AAQoL (p less than .0001). A significant reduction on Clinical Global Impression--Improvement (CGI-I), HAM-D, STAI, and ASRS scores was observed (p less than .0001). No serious adverse event was reported. Conclusion: Treatment of adult ADHD patients with OROS MPH improves QoL. (Contains 5 figures.) (As Provided).
Anmerkungen	SAGE Publications. 2455 Teller Road, Thousand Oaks, CA 91320. Tel: 800-818-7243; Tel: 805-499-9774; Fax: 800-583-2665; e-mail: journals@sagepub.com; Web site: http://sagepub.com
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10